CapsuleX and cisplatin for platinum-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer confirmed by biopsy.
- Your cancer is considered platinum-resistant, meaning it came back within 3 to 6 months after your last platinum chemo.
- You have had 2 or 3 lines of prior cancer treatment, and your cancer progressed within 6 months of your last platinum treatment.
- You have at least one tumor that can be measured on a scan, and it has not been treated with local therapy recently.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.